摘要
目的:探讨盆炎1号方经皮经穴靶向透药及口服治疗慢性盆腔炎患者血清CA125、hs-CRP、ESR的影响。方法:将2017年1月至2018年12月因慢性盆腔炎(湿热瘀结证)于我院就诊的150例患者纳入研究并按随机数字表法分为3组各50例,对照组采用盆炎1号方口服治疗,观察A组用盆炎1号方经皮经穴靶向透药,观察B组用盆炎1号方口服兼经皮经穴靶向透药治疗,28 d为1个疗程并比较3组临床疗效。结果:治疗后3组患者带下多、腰骶痛、下腹痛、经量多等症状改善,总症状积分降低,观察B组数值最低,观察A组次之,对照组最高;3组血清D-D、Hs-CRP、CA125、ESR等指标降低,观察B组数值最低,观察A组次之,对照组最高;观察B组总有效率96.00%,观察A组88.00%,对照组72.00%,观察组总有效率均高于对照组;对照组不良反应总发生率14.00%,观察A组总发生率8.00%,观察B组总发生率14.00%,差异无统计学意义。结论:盆炎1号方经皮经穴靶向透药治疗慢性盆腔炎效果显著,联合口服时疗效更好,值得临床推广。
Objective:To investigate the effect of patients’serum CA125,hs-CRP and ESR with chronic pelvic inflammatory Disease which treated with Oral and percutaneous targeted administration of pelvic inflammation prescription 1.Methods:From January 2017 to December 2018,150 patients with chronic pelvic inflammatory disease(damp-heat syndrome)were randomly divided into three groups(n=50)and control group(n=50)The rats in group A were treated with paclitaxel 1 on the percutaneous transcutaneous drug.For a course of treatment.Comparison of the three groups of patients with symptomatic points,inflammatory indicators to improve the situation,compared the three groups of clinical efficacy differences.Results:After treatment,the patients in the three groups had more symptoms,lower lumbosacral pain,lower abdominal pain,increased amount of symptoms and so on.The total symptom score decreased,and the value of group B was the lowest.The observation group A was the highest in the control group.The levels of serum D-dimer(DD),Hs-CRP,CA125 and ESR were lower in group 3,and the lowest in group B was observed.The total effective rate was 96.00%(48/50)in group B,and 88.00%(44/50)in group A and 72.00%(36/50)in control group.The total effective rate were higher than the control group.Conclusion:The treatment of chronic pelvic inflammatory disease is effective in the treatment of chronic pelvic inflammatory disease,and the effect is better when combined with oral administration.It can be better to improve symptoms and inflammation.
作者
饶赟
李佩双
方家
吴飞华
梁瑞宁
RAO Yun;LI Pei-shuang;FANG Jia;WU Fei-hua;LIANG Rui-ning(Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,Nanchang 330006,China)
出处
《中国中医基础医学杂志》
CAS
CSCD
北大核心
2019年第10期1393-1396,共4页
JOURNAL OF BASIC CHINESE MEDICINE
基金
国家自然科学基金资助项目(81560783)-滋肾清热利湿化瘀方干预PCOS颗粒细胞影响卵泡发育分子机制研究
江西省卫生计生委中医药科研课题(2016A097)-盆炎1号方经皮穴靶向透药治疗慢性盆腔炎的临床研究
关键词
盆炎1号方
经皮经穴靶向透药
慢性盆腔炎
CA125
炎症指标
高凝状态
Pelvic inflammation prescription 1
Percutaneous meridian targeting drug
Chronic pelvic inflammatory disease
CA125
Inflammation index
Hypercoagulable state
